Syn2869, a New Potent Antifungal Triazole for the Treatment of Systemic and Superficial Fungal Infections: In Vitro Activity against Clinical Isolates of Yeast and Dermatphytes.

S.M. SALAMA, A. GANDHI, H. ATWAL, J. SIMON, J. KHAN, R.G. MICETICH, and M. DANESHTALAB

Abstract: 

Syn2869, (2R, 3R)-2-(2,4- Diflourophenyly)-3-[4-{4-[2-(4-triflouromethyloxybenzyl)-2H-1,2,4-triazole-3-one-4-yl] phenyl}piperazin-1-yl]1-(1H-1,2,4-triazole-1-yl)butan-2-ol, is novel triazole with potent activities against a wide spectrum of fungi both in vitro and in vivo. We have determined the in vitro activity of Syn2869 against a panel of over 240 clinical isolates of yeast and filamentous fungi, and compared the results with those obtained by Fluconazole (FLU0, Itraconazole (ITRA), and Amphotericin B (AMB). The test procedures applied were in accordance with the NCCLS M27-A recommended broth dilution method. The minimum inhibitory concentration (MIC) was defined as the lowest concentration which resulted in an 80% reduction in turbidity as compared to a drug-free control tube for the Azoles and no visible growth as compared to the drug-free tube for AMB. The MIC90} of Syn2869 (micro g/ML) against strains of Candida albicans was 0.09 (range 100), Cryptococcus neoformans was 0.19 (range
1998

abstract No: 

NULL

Full conference title: 

38th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 38th